Sustained release pharmaceutical composition of solid medical material

• US 4,343,789 A
• Filed: 07/02/1980
• Issued: 08/10/1982
• Est. Priority Date: 07/05/1979
• Status: Expired due to Term

• Current Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Astellas Pharma Incorporated)
• Original Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Astellas Pharma Incorporated)
• Inventors: Ohmura, Tadayoshi, Aruga, Masayoshi, Yoneya, Satoru, Sonobe, Takashi, Kawata, Hiroitsu, Sone, Chiharu
• Primary Examiner(s): Rose, Shep K.
• Application Number:
  US06/165,244
• Time in Patent Office: 769 Days
• Field of Search: 424/19-22, 424/35, 424/78, 424/80, 424/362, 264/117, 264/118
• US Class Current: 514/356
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/1611 Inorganic compounds

Abstract

Sustained release pharmaceutical composition of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment): and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).

Claims

1. A sustained release pharmaceutical composition comprising a coronary and cerebral vascular dilating-effective amount of an amorphous form of nicardipine or a salt thereof, and polyethylene oxide in the form of a fine powder or fine particle granules.

2. A pharmaceutical composition as claimed in claim 1 which contains (i) said amorphous nicardipine or salt thereof, (ii) said polyethylene oxide and (iii) at least one basic substance (1st component) selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinmethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and an amino acid.

3. A pharmaceutical composition as claimed in claim 1 which contains (i) said amorphous nicardipine or salt thereof, (ii) said polyethylene oxide, (iii) said 1st component(s) and at least one basic substance (2nd component) selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerine, glycerine fatty acid ester and a vegetable oil.

4. The composition as claimed in claim 1 in which the amorphous nicardipine or its salt is obtained by friction pulverizing nicardipine or its salt to a fine powder.

5. The composition as claimed in claim 4 in which the friction pulverizing is performed by a ball mill or a vibrating ball mill.

6. A process of producing a sustained release pharmaceutical composition as claimed in claim 1 characterized by compounding said nicardipine or salt thereof in amorphous form with said polyethylene oxide.

7. The process of producing a sustained release pharmaceutical composition as claimed in claim 2 which comprises dissolving nicardipine or salt thereof in amorphous form and said 1st component(s) in water or an organic solvent, distilling off the solvent, and then adding said polyethylene oxide.

8. The process of producing a sustained release pharmaceutical composition as claimed in claim 3 which comprises dissolving said nicardipine or salt thereof in amorphous form, said 1st component(s) and said 2nd component(s) in water or an organic solvent, distilling off the solvent, and then adding said polyethylene oxide.

9. The process of producing a sustained release pharmaceutical composition as claimed in claim 2 which comprises dissolving said nicardipine or salt thereof in amorphous form, said 1st component(s) and said polyethylene oxide in water or an organic solvent, and then distilling off the solvent.

10. The process of producing a sustained release pharmaceutical composition as claimed in claim 3 which comprises dissolving said nicardipine or salt thereof in amorphous form, said 1st component(s), said 2nd component(s) and said polyethylene oxide in water or an organic solvent, and distilling off the solvent.

11. The composition as claimed in claim 1, wherein said nicardipine is in the form of amorphous nicardipine base.

12. The composition as claimed in claim 1, wherein said amorphous salt of nicardipine is amorphous nicardipine hydrochloride.

13. The process as claimed in claim 6, in which said amorphous nicardipine or salt thereof is obtained by friction pulverizing nicardipine or a salt thereof to a fine powder.